Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity
申请人:Oklahoma Medical Research Foundation
公开号:US20030017148A1
公开(公告)日:2003-01-23
Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease believed to be caused by an inflammatory process in the pancreas leading to selective destruction of the &bgr; cells. Inducible cyclooxygenase (COX-2) is expressed under inflammatory conditions and its product prostaglandin E
2
(PGE
2
) is an important inflammation mediator. Administration of the selective COX-2 inhibitor such as, e.g., NS-398 prevents the onset of diabetes in mice brought on by multiple low-doses of streptozotocin (STZ). Histological observations indicated that STZ-mediated destruction of &bgr; cells was prevented by NS-398 treatment. Delayed (day 3) administration of NS-398 was also protective in this model. These results demonstrate the critical importance of COX-2 activity in autoimmune destruction of &bgr; cells, and point to the fact that COX-2 inhibition should provide a preventive therapy against IDDM or other autoimmune problems, including allograft rejection. Inhibitors of NF-&kgr;B activation may also be used to prevent IDDM and allograft rejection.
胰岛素依赖型糖尿病(IDDM)是一种自身免疫性疾病,据信是由胰腺炎症过程导致&bgr;细胞选择性破坏引起的。诱导环氧化酶(COX-2)在炎症条件下表达,其产物前列腺素 E
2
(PGE
2
是一种重要的炎症介质。服用选择性 COX-2 抑制剂(如 NS-398)可防止小鼠因多次服用低剂量链脲佐菌素(STZ)而引发糖尿病。组织学观察表明,NS-398 能防止 STZ 介导的 &bgr; 细胞破坏。延迟(第 3 天)服用 NS-398 对该模型也有保护作用。这些结果表明,COX-2 的活性在 &bgr; 细胞的自身免疫性破坏中至关重要,并指出抑制 COX-2 可为 IDDM 或其他自身免疫性问题(包括异体移植排斥反应)提供预防性疗法。NF-&kgr;B激活抑制剂也可用于预防IDDM和异体移植排斥反应。